| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Talimogene laherparepvec |
| Brand | Imlygic® |
| Indication | For the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. |
| Assessment Process | |
| Rapid review commissioned | 16/02/2016 |
| Rapid review completed | 14/03/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
Not considered cost-effective due to non-submission of full pharmacoeonomic assessment.